Anthony Hunter, MD, Winship Cancer Institute of Emory University, Atlanta, GA, discusses the ongoing Phase I LIMBER‐103 study (NCT04279847), which is investigating the safety and efficacy of INCB057643, a BET inhibitor, in patients with myelofibrosis (MF) and other myeloproliferative neoplasms (MPNs) through multiple treatment arms. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.